Lowering Drug Prices by Once Again Putting Americans First
The White House
This executive order directs the Department of Health and Human Services (HHS) and other federal agencies to implement a series of regulatory changes aimed at reducing prescription drug costs.
The primary focus is modifying existing Medicare negotiation frameworks, increasing competition through generic approvals and drug importation, and increasing transparency around pharmacy benefit managers and hospital acquisition costs.
For seniors and Medicare beneficiaries, this order seeks to address recent increases in Medicare Part D premiums and reshape how Medicare pays for high-cost medications. It directs agencies to formulate plans to stabilize these insurance premiums and tests new payment models to ensure Medicare gets better value for expensive drugs.
It aims to prevent Medicare rules from incentivizing doctors to administer drugs in more expensive hospital settings rather than their local offices.
For uninsured or underinsured Americans, a critical provision ties federal funding for community health centers to their willingness to pass along steep discounts on life-saving medications.
If you have a high deductible or lack healthcare insurance, these health centers will be required to offer insulin and injectable epinephrine at or below the heavily discounted price the clinic pays, plus a small administration fee.
Finally, the order targets the broader pharmaceutical supply chain by directing the FDA to streamline drug importation programs from other countries and accelerate the approval of cheaper generic alternatives.
It also tasks the Department of Labor with proposing regulations to increase transparency around Pharmacy Benefit Managers (PBMs) so employers can better understand the direct and indirect fees impacting workers' health coverage.
